These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17726671)

  • 1. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis.
    Chilton F; Collett RA
    Musculoskeletal Care; 2008 Mar; 6(1):1-14. PubMed ID: 17726671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
    Anink J; Otten MH; Gorter SL; Prince FH; van Rossum MA; van den Berg JM; van Pelt PA; Kamphuis S; Brinkman DM; Swen WA; Swart JF; Wulffraat NM; Dolman KM; Koopman-Keemink Y; Hoppenreijs EP; Armbrust W; ten Cate R; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
    Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
    Curr Med Res Opin; 2007 Aug; 23(8):1749-59. PubMed ID: 17588306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
    Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G
    Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M; Rødevand E; Skomsvoll JF
    Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.